Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$8.39
+2.1%
$7.72
$4.11
$9.50
$1.75B1.752.81 million shs3.21 million shs
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$7.35
+2.1%
$8.16
$6.20
$12.65
$2.26B0.792.62 million shs3.68 million shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$108.07
-0.4%
$108.78
$69.51
$129.90
$2.08B1.07120,497 shs102,809 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.41
-3.4%
$1.64
$1.15
$2.04
$946.89M1.783.90 million shs3.30 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
0.00%+13.38%+7.15%+9.82%+99.29%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
0.00%+7.61%-14.44%-23.52%-30.27%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
0.00%+2.95%-1.49%-6.05%+52.21%
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.00%-0.70%-18.97%-4.73%+14.63%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
4.4671 of 5 stars
4.42.00.04.23.41.70.6
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
4.2777 of 5 stars
3.42.00.04.33.30.81.9
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
4.3022 of 5 stars
3.50.00.04.43.42.51.9
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.4666 of 5 stars
3.43.00.04.42.05.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
2.86
Moderate Buy$15.5785.60% Upside
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.78
Moderate Buy$16.75127.89% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
3.00
Buy$146.4335.49% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.75
Moderate Buy$2.7595.04% Upside

Current Analyst Ratings Breakdown

Latest OPK, FOLD, LGND, and BCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/25/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
4/11/2025
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$11.00 ➝ $11.00
4/10/2025
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
4/10/2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$143.00
4/7/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/19/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/12/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/12/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
3/3/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
2/28/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
2/25/2025
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$10.00 ➝ $11.00
(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$450.71M3.89N/AN/A($2.22) per share-3.78
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$528.30M4.27N/AN/A$0.63 per share11.67
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$167.13M12.47$4.43 per share24.39$40.39 per share2.68
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.14M1.33N/AN/A$1.80 per share0.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-$226.54M-$0.43N/AN/AN/A-30.01%N/A-24.06%5/5/2025 (Estimated)
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
-$151.58M-$0.18N/A17.091.51-10.62%12.44%2.60%5/1/2025 (Estimated)
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$52.15M-$0.1643.0629.13N/A29.68%4.95%4.39%5/8/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$188.86M-$0.09N/AN/AN/A-18.65%-9.76%-6.46%4/30/2025 (Estimated)

Latest OPK, FOLD, LGND, and BCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.23N/AN/AN/A$37.84 millionN/A
5/5/2025Q1 2025
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-$0.07N/AN/AN/A$126.83 millionN/A
5/1/2025Q1 2025
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$0.08N/AN/AN/A$136.32 millionN/A
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07N/AN/AN/A$163.13 millionN/A
2/27/2025Q4 2024
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.08$0.01+$0.09$0.01$155.42 million$183.60 million
2/24/2025Q4 2024
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-$0.07-$0.13-$0.06-$0.13$126.64 million$131.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/AN/AN/AN/AN/A
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/A
2.78
2.73
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.01
3.39
2.42
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/A
12.49
11.81
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.30
2.97
2.69

Institutional Ownership

CompanyInstitutional Ownership
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
85.88%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
91.28%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%

Insider Ownership

CompanyInsider Ownership
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
4.80%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.20%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
5.90%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
530208.96 million197.19 millionOptionable
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
480307.24 million292.23 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
8019.28 million17.78 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
4,200671.55 million359.94 millionOptionable

Recent News About These Companies

Opko Health initiated with a Neutral at JPMorgan
OPKO Health, Inc. stock logo
OPKO Health (OPK) Projected to Post Earnings on Wednesday

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioCryst Pharmaceuticals stock logo

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.39 +0.17 (+2.07%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$8.32 -0.07 (-0.82%)
As of 04/25/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Amicus Therapeutics stock logo

Amicus Therapeutics NASDAQ:FOLD

$7.35 +0.15 (+2.08%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$7.38 +0.03 (+0.34%)
As of 04/25/2025 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$108.07 -0.48 (-0.44%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$108.18 +0.12 (+0.11%)
As of 04/25/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.41 -0.05 (-3.42%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$1.45 +0.04 (+2.77%)
As of 04/25/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.